You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5349 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    olaparib - For the maintenance treatment of BRCA-mutated, high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
olaparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Document
Jun 2018
Document
Jun 2018
Document
Jun 2018
Document
Jun 2018
Document
Jun 2018
Document
Jun 2018
Document
Jun 2018
Drug
Other Name(s): Rituxan® SC
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Guidelines and Advice
Status: Current
ID: ES SMG-2
Jun 2018
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Document
Jun 2018

Pages